Vaishali Pharma (VAISHALI) Stock Overview
Engages in the pharmaceutical business in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VAISHALI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Vaishali Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹7.76 |
| 52 Week High | ₹13.10 |
| 52 Week Low | ₹4.75 |
| Beta | 0.38 |
| 1 Month Change | 5.43% |
| 3 Month Change | -3.36% |
| 1 Year Change | -37.37% |
| 3 Year Change | -42.98% |
| 5 Year Change | 94.00% |
| Change since IPO | 99.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| VAISHALI | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.0% | -1.7% | -1.0% |
| 1Y | -37.4% | 11.0% | -1.5% |
Return vs Industry: VAISHALI underperformed the Indian Pharmaceuticals industry which returned 11% over the past year.
Return vs Market: VAISHALI underperformed the Indian Market which returned -1.5% over the past year.
Price Volatility
| VAISHALI volatility | |
|---|---|
| VAISHALI Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.7% |
Stable Share Price: VAISHALI has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: VAISHALI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Hemanth Pathak | www.vaishalipharma.com |
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products.
Vaishali Pharma Limited Fundamentals Summary
| VAISHALI fundamental statistics | |
|---|---|
| Market cap | ₹1.01b |
| Earnings (TTM) | ₹41.65m |
| Revenue (TTM) | ₹1.09b |
Is VAISHALI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VAISHALI income statement (TTM) | |
|---|---|
| Revenue | ₹1.09b |
| Cost of Revenue | ₹951.23m |
| Gross Profit | ₹136.49m |
| Other Expenses | ₹94.85m |
| Earnings | ₹41.65m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.32 |
| Gross Margin | 12.55% |
| Net Profit Margin | 3.83% |
| Debt/Equity Ratio | 26.8% |
How did VAISHALI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/24 20:22 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vaishali Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.